- Home
- APLS vs FOLD Comparison
APLS vs FOLD Comparison
Compare APLS & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- FOLD
- Stock Information
- Founded
- APLS 2009
- FOLD 2002
- Country
- APLS United States
- FOLD United States
- Employees
- APLS N/A
- FOLD N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- APLS Health Care
- FOLD Health Care
- Exchange
- APLS Nasdaq
- FOLD Nasdaq
- Market Cap
- APLS 2.9B
- FOLD 2.5B
- IPO Year
- APLS 2017
- FOLD 2007
- Fundamental
- Price
- APLS $20.39
- FOLD $9.49
- Analyst Decision
- APLS Buy
- FOLD Buy
- Analyst Count
- APLS 19
- FOLD 7
- Target Price
- APLS $32.83
- FOLD $30.29
- AVG Volume (30 Days)
- APLS 3.4M
- FOLD 5.0M
- Earning Date
- APLS 10-30-2025
- FOLD 11-04-2025
- Dividend Yield
- APLS N/A
- FOLD N/A
- EPS Growth
- APLS N/A
- FOLD N/A
- EPS
- APLS 0.36
- FOLD N/A
- Revenue
- APLS $1,016,397,000.00
- FOLD $598,704,000.00
- Revenue This Year
- APLS $25.39
- FOLD $21.12
- Revenue Next Year
- APLS N/A
- FOLD $21.23
- P/E Ratio
- APLS $56.77
- FOLD N/A
- Revenue Growth
- APLS 42.11
- FOLD 21.28
- 52 Week Low
- APLS $16.10
- FOLD $5.51
- 52 Week High
- APLS $35.72
- FOLD $10.43
- Technical
- Relative Strength Index (RSI)
- APLS 39.49
- FOLD 67.88
- Support Level
- APLS $18.93
- FOLD $8.69
- Resistance Level
- APLS $30.48
- FOLD $9.64
- Average True Range (ATR)
- APLS 1.29
- FOLD 0.38
- MACD
- APLS -0.37
- FOLD 0.03
- Stochastic Oscillator
- APLS 13.94
- FOLD 85.29
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.